688180 君實生物
按盤價 
35.570 +0.090 (+0.254%) | 2026/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 1,696,211 | 45.18% | 2,498,420 | 1,948,317 | 1,502,550 | 1,453,493 | |
| 減：營業總成本 | 1,788,098 | 7.77% | 3,444,363 | 3,215,859 | 3,811,860 | 4,102,931 | |
| 其中:營業成本 | 285,274 | 22.45% | 466,505 | 410,682 | 540,976 | 504,308 | |
| 財務費用 | 74,218 | 190.52% | 65,273 | (144) | (67,086) | (80,955) | |
| 資產減值損失 | (131,506) | 159.18% | (98,098) | (88,179) | (126,314) | (21,974) | |
| 公允價值變動收益 | 25,736 | -53.64% | 57,210 | (47,679) | (149,177) | (9,277) | |
| 投資收益 | 108,091 | -632.93% | (106,417) | (23,554) | 73,990 | (41,932) | |
| 其中：對聯營企業和合營企業的投資收益 | (43,205) | 71.39% | (116,102) | (35,026) | (60,485) | (71,031) | |
| 營業利潤 | (19,012) | -96.00% | (999,463) | (1,338,825) | (2,457,442) | (2,665,914) | |
| 利潤總額 | (33,380) | -93.12% | (1,023,274) | (1,357,557) | (2,491,695) | (2,677,184) | |
| 減：所得稅費用 | 7,444 | -138.10% | (13,881) | 22,552 | 43,995 | (93,107) | |
| 淨利潤 | (40,824) | -91.23% | (1,009,393) | (1,380,109) | (2,535,689) | (2,584,077) | |
| 減：非控股權益 | (62,487) | 17.95% | (134,219) | (99,182) | (252,257) | (196,028) | |
| 股東淨利潤 | 21,663 | -105.25% | (875,174) | (1,280,926) | (2,283,432) | (2,388,050) | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.020 | -104.76% | -0.870 | -1.300 | -2.320 | -2.600 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 5.789 | -6.73% | 5.874 | 5.946 | 7.260 | 9.650 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 27/08/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
